1. Statins and New-Onset Diabetes REAL Updates and Clinical Implications

3. Unwavering Benefits of Statins

4. Statins and the Development of Diabetes

5. WOSCOPS Pravastatin Reduction in LDL-C/Reduced CAD by 30%

6. JUPITER Rosuvastatin Therapy and Diabetes Risk

7. The Nudge Into T2D

8. Key Factors for Risk Reduction

9. Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID)

10. LIPID Results Summary

11. Pitavastatin Head-to-Head Statin Trials

12. REAL-CAD

13. Baseline Characteristics

14. Primary Endpoint (CV Death/MI/Ischemic Stroke/UA)

15. Serial Changes in Lipid Parameters and hs-CRP

16. Safety Outcomes

17. Pitavastatin Has Neutral Effect on FBG Across Dose Range

18. Potential Mechanism at Play

19. Application to Various Populations

20. Main Take-Home Messages

21. Patients With Risk Factors Need Education

22. Patient Education Team Approach

23. Final Thought

24. Abbreviations

25. Abbreviations (cont)